Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Naylor-Olsen

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Current Medicinal Chemistry|July 21, 1998
Thrombin inhibitor designP E Sanderson, A M Naylor-Olsen
Journal of Medicinal Chemistry|March 14, 1997
Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active siteT J Tucker, W C Lumma, A M Mulichak, et al.
Journal of Medicinal Chemistry|April 17, 1998
Design of novel, potent, noncovalent inhibitors of thrombin with nonbasic P-1 substructures: rapid structure-activity studies by solid-phase synthesisW C Lumma, K M Witherup, T J Tucker, et al.
Journal of Medicinal Chemistry|August 18, 1995
Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonistM E Duggan, A M Naylor-Olsen, J J Perkins, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Identification and SAR for a selective, nonpeptidyl thrombin inhibitorA M Naylor-Olsen, G S Ponticello, S D Lewis, et al.
Bioorganic & Medicinal Chemistry Letters|April 17, 1999
Nonpeptide glycoprotein IIB/IIIA inhibitors. 19. A new design paradigm employing linearly minimized, centrally constrained, exosite inhibitorsG D Hartman, M E Duggan, W F Hoffman, et al.
Journal of Medicinal Chemistry|November 14, 1997
Synthesis of a series of potent and orally bioavailable thrombin inhibitors that utilize 3,3-disubstituted propionic acid derivatives in the P3 positionT J Tucker, W C Lumma, S D Lewis, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
C6 modification of the pyridinone core of thrombin inhibitor L-374,087 as a means of enhancing its oral absorptionR C Isaacs, K J Cutrona, C L Newton, et al.
Bioorganic & Medicinal Chemistry Letters|January 1, 1999
L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitorP E Sanderson, K J Cutrona, B D Dorsey, et al.
Journal of Medicinal Chemistry|November 26, 1997
Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 positionD M Feng, S J Gardell, S D Lewis, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Current Medicinal Chemistry|July 21, 1998
Thrombin inhibitor designP E Sanderson, A M Naylor-Olsen
Journal of Medicinal Chemistry|March 14, 1997
Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active siteT J Tucker, W C Lumma, A M Mulichak, et al.
Journal of Medicinal Chemistry|April 17, 1998
Design of novel, potent, noncovalent inhibitors of thrombin with nonbasic P-1 substructures: rapid structure-activity studies by solid-phase synthesisW C Lumma, K M Witherup, T J Tucker, et al.
Journal of Medicinal Chemistry|August 18, 1995
Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonistM E Duggan, A M Naylor-Olsen, J J Perkins, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Identification and SAR for a selective, nonpeptidyl thrombin inhibitorA M Naylor-Olsen, G S Ponticello, S D Lewis, et al.
Bioorganic & Medicinal Chemistry Letters|April 17, 1999
Nonpeptide glycoprotein IIB/IIIA inhibitors. 19. A new design paradigm employing linearly minimized, centrally constrained, exosite inhibitorsG D Hartman, M E Duggan, W F Hoffman, et al.
Journal of Medicinal Chemistry|November 14, 1997
Synthesis of a series of potent and orally bioavailable thrombin inhibitors that utilize 3,3-disubstituted propionic acid derivatives in the P3 positionT J Tucker, W C Lumma, S D Lewis, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
C6 modification of the pyridinone core of thrombin inhibitor L-374,087 as a means of enhancing its oral absorptionR C Isaacs, K J Cutrona, C L Newton, et al.
Bioorganic & Medicinal Chemistry Letters|January 1, 1999
L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitorP E Sanderson, K J Cutrona, B D Dorsey, et al.
Journal of Medicinal Chemistry|November 26, 1997
Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 positionD M Feng, S J Gardell, S D Lewis, et al.
Pageof 2